Clinical Trial Update: Managed Access Programs for TQJ230, Pelacarsen

View source ↗

Summary

Clinical trial update notes available managed access programs for Pelacarsen (TQJ230) targeting atherosclerotic cardiovascular disease, sponsored by Novartis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease

Drugs mentioned

• Pelacarsen (TQJ230) (pelacarsen)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Atherosclerotic Cardiovascular Disease, ASCVD | Status: AVAILABLE